Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05159778
Title Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors HiberCell, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
The University of Arizona Cancer Center - North Campus Tucson Arizona 10032 United States Details
The University of Arizona Cancer Center Tucson Arizona 85719 United States Details
University of Colorado at Denver Denver Colorado 80045 United States Details
Mt. Sinai (Miami) Miami Beach Florida 33140 United States Details
University of Miami and Clinics -Sylvester Comprehensive Cancer Center Miami Florida 33136 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Louisiana State University Health Sciences Center - New Orleans New Orleans Louisiana 70112 United States Details
HealthPartners Cancer Research Center Saint Louis Park Minnesota 55426 United States Details
St. Luke's Cancer Institute Kansas City Missouri 64111 United States Details
St. Vincent - Frontier Cancer Center Billings Montana 59102 United States Details
University of New Mexico Comprehensive Cancer Center Albuquerque New Mexico 87131 United States Details
Columba University Medical Center New York New York 10032 United States Details
Stony Brook University Stony Brook New York 11794 United States Details
Thomas Jefferson University- Sidney Kimmel Cancer Center Philadelphia Pennsylvania 19107 United States Details
Baptist Clinical Research Institute Memphis Tennessee 38120 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field